Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Watson Says Received Favorable Ruling Over Generic Sanctura XR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2012 | 12:19am CEST

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on ACTAVIS INC
06/27DJMayne Pharma Buys US Drugs from Teva, Allergan for $652 Million
06/21DJTeva and Allergan Sell Generic Drugs to Impax In Latest Divestiture
06/21DJTeva and Allergan Sell Generic Drugs to Impax In Latest Divestiture
06/17DJALLERGAN : Former Warner Chilcott Executive Acquitted of Kickbacks Charge
06/16DJTeva, Looking to Close Actavis Deal, Sells $40 Million Portfolio to Sagent
06/14DJLILLY : German Supreme Court Grants Appeal in Dispute With Actavis
05/31DJALLERGAN : Icahn Takes Big Stake in Allergan, Endorses Drugmaker's CEO
05/26 Anacor received rival bid before Pfizer deal - filing
05/17DJPfizer Buys Anacor In Turn to Smaller Deals -- WSJ
05/16DJPfizer to Buy Anacor for $4.5 Billion--2nd Update
Advertisement
Income Statement Evolution
More Financials